The early stage SARS-CoV-2 immune response including antibody kinetics in out of hospital patients with mild COVID-19 symptoms

• Conditions: coronavirus; COVID-19; 10047438

• Registration Number: NL-OMON50008
• Lead Sponsor: Reade, reumatologie en revalidatie te Amsterdam

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 15 April 2024

Recruitment & Eligibility

• Status: Pending
• Sex: Not specified
• Target Recruitment: 14

Inclusion Criteria

1. Age > 18 years;
2. Symptoms associated with a COVID-19 infection;
3. Travelled to an endemic region or have contact with a person who is
suspected for/or diagnosed with a COVID-19 infection or had a SARS-CoV-2
positive PCR;
4. Mild COVID-19 symptoms which did not require hospital admittance;
5. No more than 10 days between symptoms associated with a COVID-19 infection
and the screening visit.

Exclusion Criteria

1. Language problems precluding the completion of the questionnaire or
understanding the informed consent;
2. Likelihood of absence in the next 4 weeks.

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>The geometric mean titres of total and isotype-specific (including IgM, IgG)<br /><br>antibodies in patients with mild COVID-19 symptoms which did not require<br /><br>hospital admittance.</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>none.</p><br>